Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ: CGON )

20.62 -0.11 (-0.53%)
Streaming Delayed Price Updated: 12:30 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,348
Open 20.79
Bid (Size) 20.57 (3)
Ask (Size) 20.69 (2)
Prev. Close 20.73
Today's Range 20.57 - 21.41
52wk Range 14.80 - 46.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga

Performance

YTD
-28.82%
-28.82%
1 Month
-27.73%
-27.73%
3 Month
-31.74%
-31.74%
6 Month
-42.09%
-42.09%
1 Year
-43.21%
-43.21%

More News

Read More
Friday's after hours session: top gainers and losers
Via Chartmill
3 Analysts Assess CG Oncology: What You Need To Know
Via Benzinga
Why CG Oncology (CGON) Stock Is Down 9%
Via Benzinga
Demystifying CG Oncology: Insights From 7 Analyst Reviews
Via Benzinga
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts
Via Benzinga
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
Via Benzinga
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Pricing of Public Offering
From CG Oncology Inc.
Via GlobeNewswire
Nasdaq Jumps 300 Points To Record Highs
Via Talk Markets
Topics Stocks / Equities
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate
Via Benzinga
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.